Key result
Long-term use of depot medroxyprogesterone acetate significantly impaired endothelium-dependent flow-mediated dilatation compared with controls (1.1% vs 8.0%; P<0.01).
Why the study?
Does long-term use of depot medroxyprogesterone acetate impair arterial endothelial function in young women?
Observational (n=23)
Does long-term use of depot medroxyprogesterone acetate impair arterial endothelial function in young women?
Absolute Event Rate: 1.1% vs 8%
p-value: p=<0.01
Long-term use of depot medroxyprogesterone acetate in young women is associated with impaired arterial endothelial function, likely mediated by hypoestrogenism.
May indicate vascular effects of long-term DMPA in young women; leaves open clinical relevance pending larger prospective studies.
BACKGROUND: Depot medroxyprogesterone acetate (DMPA) inhibits proliferation of ovarian follicles, resulting in anovulation and a decrease in circulating estrogen; the latter action is potentially disadvantageous to cardiovascular health. We therefore investigated the vascular effects of long-term contraceptive DMPA in young women. METHODS AND RESULTS: Endothelium-dependent (hyperemia-induced flow-mediated dilatation [FMD]) and -independent (glyceryl trinitrate [GTN]) changes in brachial artery area were measured using cardiovascular magnetic resonance in 13 amenorrheic DMPA users (>1 year use; mean age 29+/-4 years) and in 10 controls (mean age 30+/-4 years, P=0.25) with regular menstrual cycles after validation of the technique. FMD and GTN responses were measured just before repeat MPA injection and 48 hours later (n=12) in DMPA users and during menstruation and midcycle (n=9) in controls. Serum-estradiol levels (S-estradiol) were measured at both visits. FMD was reduced in DMPA users compared with controls during menstruation (1.1% versus 8.0%, respectively P<0.01) without differences in GTN responses. S-estradiol levels in DMPA users were significantly lower than in controls during menstruation (58 versus 96 pmol/L, P<0.01). High levels of circulating MPA 48 hours after injection were not linked to an additional impairment in FMD (2.0% versus 3.1%, P=0.23). Estradiol levels were significantly correlated to FMD (r=0.43, P<0.01). CONCLUSIONS: Endothelium-dependent arterial function measured by cardiovascular magnetic resonance is impaired in chronic users of DMPA, and hypoestrogenism may be the mechanism of action. DMPA might adversely affect cardiovascular health, and in particular its use in women with cardiovascular disease should be additionally evaluated.
No takes yet. Share an insight, caveat, or question.
Sørensen et al. (2002) conducted an observational in Healthy women (n=23). Depot medroxyprogesterone acetate (DMPA) vs. Controls with regular menstrual cycles was evaluated on Endothelium-dependent hyperemia-induced flow-mediated dilatation (FMD) during menstruation (p=<0.01). Long-term use of depot medroxyprogesterone acetate significantly impaired endothelium-dependent flow-mediated dilatation compared with controls (1.1% vs 8.0%; P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: